Year: 2016

New Breast Cancer Research Highlights BGB324 In Overcoming Immunotherapy Resistance

December 8, 2016

Presentation at San Antonio Breast Cancer Symposium 2016 Bergen, Norway, December 8, 2016 – Leading…

Read More

BerGenBio Reports Promising BGB324 Phase I/II Monotherapy Data in Patients with Lung Cancer at the EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium

December 5, 2016

Long term disease stabilisation observed highlighting importance of AXL in NSCLC Bergen, Norway, November 29,…

Read More

BerGenBio Presents Promising Phase I Clinical & Biomarker Data From First In Class Axl Inhibitor BGB324 In AML at the ASH 2016

December 5, 2016

Bergen: Leading oncology biopharmaceutical company BerGenBio AS, today presented clinical and biological data from a…

Read More

New BGB324 study points to novel mechanism to enhance immunotherapy efficacy

September 26, 2016

Presented at CRI-CIMT-EATI-AACR - The 2nd International Cancer Immunotherapy Conference Bergen, Norway, September 25, 2016…

Read More

BerGenBio Reports First-in-Patient Phase 1 Data for BGB324 in Patients with Myeloid Malignancies at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting

July 4, 2016

Promising clinical activity with biologic activity, tolerability, and durability BerGenBio AS ("BerGenBio" or the "Company"),…

Read More

BerGenBio presents new data demonstrating that BGB324 enhances checkpoint inhibitor blockade

April 18, 2016

Bergen, Norway, April 18, 2016 – BerGenBio AS (“BerGenBio” or the “Company”) announces that preclinical…

Read More